Vera Therapeutics to present ORIGIN 3 analysis at ASN Kidney Week 2026

Vera Therapeutics said the final efficacy analysis of ORIGIN 3 for TRUTAKNA (atacicept-vymj) in IgA nephropathy will be a featured late-breaking oral presentation at the opening plenary session of ASN Kidney Week 2026.